HIGHLIGHTS
- who: Saveri Bhattacharya from the (UNIVERSITY) have published the research work: KRAS mutant lung cancer: progress thus far on an elusive therapeutic target, in the Journal: (JOURNAL)
- what: The results of this trial show an impressive benefit to patients with KRAS mutant genotype who were treated with sorafenib.
- how: This trial's pooled results found that KRAS mutational status was weakly prognostic and did not show a significant predictive benefit from adjuvant chemotherapy.
SUMMARY
In lung cancer, KRAS mutations occur frequently at codons 12 and 13 and less frequently . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.